Ideas to Action:

Independent research for global prosperity


Global Health Policy Blog


JAMA logoA combination vaccine developed to reduce the number of injections infants receive appears to provide less immunity than the vaccines administered individually, according to a study in the April 13 2005 issue of JAMA.

Jim P. Buttery and colleagues conducted a study to determine the immunogenicity and safety of a combination 9-valent pneumococcal-group C meningococcal conjugate candidate vaccine.

The researchers found:

Pnc9-MenC combination vaccine administered to infants at ages 2, 3, and 4 months demonstrated reduced group C meningococcal immunogenicity compared with MenC vaccine. The immunogenicity of concomitantly administered Hib and DTwP vaccines was also diminished. The Pnc9-MenC vaccine was safe and immunogenic for all contained pneumococcal serotypes.

Immunogenicity and Safety of a Combination Pneumococcal-Meningococcal Vaccine in Infants: A Randomized Controlled Trial Jim P. Buttery; Anna Riddell; Jodie McVernon; Tracey Chantler; Laura Lane; Jane Bowen-Morris; Linda Diggle; Rhonwen Morris; Anthony Harnden; Steven Lockhart; Andrew J. Pollard; Keith Cartwright; E. Richard Moxon JAMA. 2005;293:1751-1758. Abstract

Related Topics:


CGD blog posts reflect the views of the authors, drawing on prior research and experience in their areas of expertise. CGD is a nonpartisan, independent organization and does not take institutional positions.